Search research articles
Contact Us
Filters
Showing results (11-20 of 46) with videos related to
Page
of 5
Sort By:
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
July 24, 2013
Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases
M Uhrig, M Sedlmair, H P Schlemmer, et al.
Oncology
|
April 15, 2015
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib
Maria-Katharina Ganten, Max Schuessler, Thomas Bruckner, et al.
Der Radiologe
|
January 29, 2003
[Follow up of Crohn's disease under therapy with hydro-MRI]
M Ganten, J Encke, P Flosdorff, et al.
Oncology
|
October 19, 2012
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma
Ronald Koschny, Daniel Gotthardt, Christiane Koehler, et al.
VASA. Zeitschrift Fur Gefasskrankheiten
|
February 21, 2009
Intracranial dissection during carotid endarterectomy treated by carotid stenting
N Attigah, M Ganten, A Hyhlik-Dürr, et al.
Pathology, Research and Practice
|
December 4, 2009
Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease
Sylvia Brost, Ronald Koschny, Jaromir Sykora, et al.
European Journal of Clinical Investigation
|
January 16, 2007
Helicobacter pylori-induced apoptosis in T cells is mediated by the mitochondrial pathway independent of death receptors
T M Ganten, E Aravena, J Sykora, et al.
Pathology, Research and Practice
|
November 26, 2013
Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection
Sylvia Brost, Anna Zimmermann, Ronald Koschny, et al.
European Journal of Radiology
|
December 19, 2012
Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib
Xu Dai, Heinz-Peter Schlemmer, Bernhard Schmidt, et al.
Hepatology (Baltimore, Md.)
|
July 23, 2005
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL
Tom M Ganten, Ronald Koschny, Tobias L Haas, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 46) with videos related to
Sort By:
Page
of 5
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
July 24, 2013
Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases
M Uhrig, M Sedlmair, H P Schlemmer, et al.
Oncology
|
April 15, 2015
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib
Maria-Katharina Ganten, Max Schuessler, Thomas Bruckner, et al.
Der Radiologe
|
January 29, 2003
[Follow up of Crohn's disease under therapy with hydro-MRI]
M Ganten, J Encke, P Flosdorff, et al.
Oncology
|
October 19, 2012
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma
Ronald Koschny, Daniel Gotthardt, Christiane Koehler, et al.
VASA. Zeitschrift Fur Gefasskrankheiten
|
February 21, 2009
Intracranial dissection during carotid endarterectomy treated by carotid stenting
N Attigah, M Ganten, A Hyhlik-Dürr, et al.
Pathology, Research and Practice
|
December 4, 2009
Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease
Sylvia Brost, Ronald Koschny, Jaromir Sykora, et al.
European Journal of Clinical Investigation
|
January 16, 2007
Helicobacter pylori-induced apoptosis in T cells is mediated by the mitochondrial pathway independent of death receptors
T M Ganten, E Aravena, J Sykora, et al.
Pathology, Research and Practice
|
November 26, 2013
Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection
Sylvia Brost, Anna Zimmermann, Ronald Koschny, et al.
European Journal of Radiology
|
December 19, 2012
Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib
Xu Dai, Heinz-Peter Schlemmer, Bernhard Schmidt, et al.
Hepatology (Baltimore, Md.)
|
July 23, 2005
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL
Tom M Ganten, Ronald Koschny, Tobias L Haas, et al.
Page
of 5